智通财经APP讯，和铂医药-B(02142)发布公告，于2025年12月30日，该公司斥资363.05万港元回购30万 股。 ...

格隆汇12月30日丨和铂医药-B(02142.HK)公告，12月30日耗资363.1万港元回购30万股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 和鉑醫藥控股有限公司 呈交日期： 2025年12月30日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02142 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | | 已發行股份（不包 ...

Core Insights - 2025 marks a pivotal year for China's innovative pharmaceuticals, with a significant increase in international collaborations and licensing agreements, indicating a shift from a pharmaceutical giant to a stronghold in the industry [1][3] - The total amount of outbound licensing agreements exceeded $100 billion, with upfront payments reaching $8.1 billion, showcasing a transition to multi-layered cooperation models [1][3] - China's biopharmaceutical market remains the second largest globally, with innovative drugs accounting for approximately 30% of global research, reflecting a critical leap from following to competing on a global scale [1][3] Internationalization - The internationalization of China's pharmaceutical industry saw explosive growth in 2025, highlighted by a surge in business development (BD) transactions and the popularity of "A+H" listings [3][4] - The total amount of outbound licensing for innovative drugs reached over $100 billion, a 75% increase from 2024, indicating a shift from merely selling products to actively engaging in global markets [3][4] - Notable BD transactions include significant agreements between major Chinese pharmaceutical companies and international firms, such as a $12.5 billion deal between Hengrui Medicine and GSK [3][4] Innovation - In 2025, advancements in cutting-edge technologies such as antibody-drug conjugates (ADC) and dual antibodies have shown promising results in cancer treatment [7][8] - The third-generation ADC technology has become mainstream, with significant efficacy demonstrated in treating solid tumors [7] - The dual antibody sector continues to lead, with Chinese companies achieving remarkable results in clinical trials, such as a 91% improvement in progression-free survival compared to existing treatments [8] Policy Support - The policy support for innovative drugs in China has reached unprecedented levels, with a notable increase in the number of approved innovative drugs [10][11] - The National Medical Products Administration approved 69 innovative drugs in 2025, a 44% increase from the previous year, covering various therapeutic areas [10] - The payment system for innovative drugs has been significantly upgraded, enhancing accessibility and affordability for patients [10][11] Mergers and Acquisitions - The pharmaceutical sector has seen a surge in mergers and acquisitions, with over 400 transactions announced globally, totaling approximately $111 billion, marking a 50% increase from 2024 [13][14] - Domestic mergers also showed strong activity, with significant deals indicating a shift towards quality improvement and resource consolidation among leading companies [13][14] - The trend reflects a transition from scale expansion to enhancing quality and efficiency, with companies focusing on high-value clinical pipelines [14]

Core Viewpoint - The Chinese innovative pharmaceutical industry is experiencing a surge in business development (BD) transactions, but the secondary market's reaction has been mixed, with many companies seeing stock price declines despite positive announcements [2][6][10]. Group 1: Recent BD Transactions - Numerous BD transactions have been announced recently, including partnerships between Jiangsu Zaiming and Ipsen, and between Akeso and AstraZeneca, among others [2]. - In 2023, over 100 license-out transactions were completed in China, totaling more than $110 billion [4]. - As of December 21, 2025, there have been 15 transactions with upfront payments exceeding $100 million, and 37 transactions with total amounts over $1 billion, ranking second only to the U.S. [5]. Group 2: Market Reactions - Following the announcement of BD transactions, stock prices have shown varied responses; for instance, Akeso's stock fell by 13.58% on December 22, while Qianxin Bio's stock rose by 1.44% on the same day [3][6]. - A total of 37 BD transactions in A-shares and Hong Kong stocks this year resulted in 21 instances of stock price increases and 15 instances of declines on the first trading day after the announcements [6]. - The overall sentiment in the market has shifted from enthusiasm to a more rational approach, with stock prices reflecting this change [8][10]. Group 3: Industry Insights - Industry experts suggest that the complexity and long-term nature of innovative drug development require a rational approach from both capital and product markets [6][10]. - The current trend indicates that many Chinese pharmaceutical companies are still reliant on the "borrowed boat" strategy for international expansion, with a focus on licensing out rather than direct commercialization [12][13]. - The choice of out-licensing models varies, with smaller companies typically opting for complete licensing, while larger firms are exploring co-development models to retain longer-term benefits [13][14].

Core Insights - China is transitioning from a technology provider to an equal partner in the global innovative drug landscape, actively participating in clinical strategy formulation and commercialization in key markets like the U.S. [1] - The recent $2.5 billion clinical trial payment to BaiLi Tianheng signals that high-value business development (BD) transactions in China's innovative drug sector are entering a phase of realization [1] - The record $60.5 billion deal between 3SBio and Pfizer marks a shift of Chinese innovative drugs from fast followers to global pioneers, highlighting the increasing importance of Chinese pharmaceutical companies in the global pharmaceutical landscape [1] - The rapid development of the rare disease drug Beijiemai® by HeYu Pharmaceutical, taking only nine years and seven months from lab to market, exemplifies the "China speed" that is reshaping global drug development efficiency standards [1] Industry Trends - The Chinese innovative drug market is projected to reach 740 billion yuan (approximately $102 billion) by 2025, with expectations to grow to nearly 2.3 trillion yuan by 2030 [2] - The period from 2015 to 2024 is critical for the evolution of the global pharmaceutical innovation landscape and the transformation of China's clinical trial system [4] - The number of innovative drug clinical trials globally has increased by 23.5% over the past decade, with oncology remaining a key research focus, accounting for 32% of trials in 2024 [5] Clinical Development - In the first half of 2025, the China Drug Evaluation Center (CDE) received 6,213 drug registration applications, a 15.83% year-on-year increase, with chemical drugs making up 65.8% of the total [6] - HeYu Pharmaceutical's Beijiemai® received approval from the National Medical Products Administration (NMPA) for treating symptomatic tenosynovial giant cell tumors (TGCT) in adults, based on Phase III trial data showing a 54% objective response rate [1][6] Business Development - By the end of October 2025, Chinese pharmaceutical companies had achieved over $110 billion in external licensing deals, surpassing the total from 2022 to 2024 [8] - The collaboration between Innovent Biologics and Takeda Pharmaceuticals, with a potential total deal value of up to $11.4 billion, exemplifies the shift towards co-development and commercialization models [8] - The trend of biotech companies deepening globalization through various models, including joint development and independent international expansion, is becoming a core engine for growth [9] Globalization Challenges - Chinese innovative drug companies face challenges in international markets, including regulatory diversity, complex drug registration processes, and inconsistent healthcare payment systems [12] - Achieving a unified approach in clinical design and compliance across different regions is crucial for successful internationalization [12] Future Outlook - The Chinese biotech sector is expected to contribute 10% to 15% of new global drug launches in the future, driven by advancements in second-generation technologies and unmet clinical needs [7] - The successful approval of Beijiemai® in China signifies a broader industry shift, indicating that Chinese companies are no longer just serving domestic patients but are aiming to meet global patient needs [14]

Investment Rating - The report does not explicitly state an investment rating for the industry [2]. Core Insights - The pathology business is entering a fast track with the National Healthcare Security Administration issuing guidelines for pricing projects in pathology services, focusing on biopsy sampling, sample processing, and digitalization of pathology data, which is expected to enhance the application of AI in the field [3][11]. - The influenza activity has peaked across the board, with reported cases in southern provinces at 9.7%, down from 11.2% the previous week, but higher than the same period in previous years [3][11]. Market Weekly Review - The pharmaceutical and biotechnology sector fell by 0.14% from December 15 to December 19, outperforming the Wind All A index (-0.15%) and the CSI 300 index (-0.28%). The rebound was weak, with segments like pharmaceutical distribution (5.59%), offline pharmacies (4.69%), and hospitals (4.15%) leading gains, while chemical preparations (-2.1%), vaccines (-0.87%), and medical R&D outsourcing (-0.87%) lagged [3][8]. - Notable stock performances included Huaren Health (55.9%), Luyuan Pharmaceutical (36.8%), and Shuyupingmin (35.7%) with significant gains, while *ST Changyao (-24%), Yipinhong (-23.7%), and Rejing Biology (-16.5%) faced substantial declines [3][11]. Industry News and Key Company Announcements - The National Healthcare Security Administration's guidelines for pathology services are expected to drive high-quality development in the sector and create new scenarios for AI-assisted technology applications [11]. - Significant collaborations and approvals were reported, including Shanghai Jinmante's partnership with Jiangsu Kangning Jerey for a breakthrough therapy designation from the FDA for JSKN003, and Novo Nordisk's submission of a marketing application for CagriSema, which showed a weight loss of 22.7% over 68 weeks in clinical trials [12][13]. - Fosun Pharma's subsidiary received FDA approval to initiate a Phase I clinical trial for HLX18, a biosimilar to Nivolumab, targeting various cancers [13][14].

Investment Rating - The report maintains a positive outlook on the pharmaceutical industry, indicating an "Overweight" rating for the sector [28]. Core Insights - The pharmaceutical sector has shown mixed performance, with the Shenwan Pharmaceutical and Biological Index down by 0.1% this week, while the Shanghai Composite Index increased by 0.03% [3][5]. - The overall valuation of the pharmaceutical sector stands at 29.2 times earnings, ranking 10th among 31 Shenwan primary industries [5][23]. Market Performance - The Shenwan Pharmaceutical and Biological Index ranked 22nd among 31 Shenwan primary sub-industries this week [3]. - The performance of various sub-sectors includes: - Raw materials (+0.5%) - Chemical preparations (-2.1%) - Traditional Chinese medicine (+0.2%) - Blood products (-0.3%) - Vaccines (-0.9%) - Other biological products (-0.7%) - Medical devices (+1.4%) - Medical consumables (+2.3%) - In vitro diagnostics (-0.8%) - Pharmaceutical distribution (+4.7%) - Offline pharmacies (+5.6%) - Medical research outsourcing (-0.9%) - Hospitals (+4.2%) [5][6]. Recent Key Events - Changchun High-tech signed an exclusive licensing agreement for GenSci098 with Yarrow, with potential milestone payments reaching up to $1.365 billion [10]. - Hansoh Pharmaceutical entered a multi-regional exclusive licensing agreement for Amivantamab with Glenmark, with potential payments exceeding $1 billion [12]. - Hengrui Medicine's subsidiary Kailera initiated three global Phase III clinical trials for HRS-9531, targeting obesity with and without diabetes [17]. - The FDA confirmed the legality of NMN as a dietary supplement, reversing a previous ban [15]. - The first invasive brain-machine interface for treating addiction-related mental disorders was approved in China [16]. Investment Opportunities - The report suggests focusing on domestic innovative drug companies due to the recovery of the CRO investment environment, highlighting companies such as Tigermed, Nossan, and others [2]. - As 2025 approaches its end, it is recommended to pay attention to valuation shifts in companies like WuXi AppTec, Hengrui Medicine, and others [2].

Investment Rating - The report maintains a positive outlook on the pharmaceutical industry, indicating an "Overweight" rating, suggesting that the industry is expected to outperform the overall market [30]. Core Insights - The report highlights recent developments in the pharmaceutical sector, including significant business development (BD) transactions involving companies like Changchun High-tech, Hansoh Pharmaceutical, and Hengrui Medicine, with potential milestone payments reaching billions of dollars [10][12][14]. - The approval of NMN as a dietary supplement in the U.S. and the submission of a new drug application for CagriSema, a GLP-1+Amylin combination therapy, are noted as key advancements in the industry [15]. - The report emphasizes the potential investment opportunities arising from the recovery of the domestic innovative drug environment, particularly in the CRO sector, with specific companies highlighted for consideration [2]. Market Performance - The report states that the Shenwan Pharmaceutical and Biological Index decreased by 0.1% this week, while the Shanghai Composite Index increased by 0.03% [3]. - Within the pharmaceutical sector, various sub-sectors showed mixed performance, with notable increases in medical supplies (+2.3%) and offline pharmacies (+5.6%), while chemical preparations (-2.1%) and blood products (-0.3%) declined [5][9]. Recent Key Events - Changchun High-tech signed an exclusive licensing agreement for GenSci098, with potential milestone payments of up to $1.365 billion [10]. - Hansoh Pharmaceutical entered into a multi-regional exclusive licensing agreement for Amivantamab, with potential payments exceeding $1 billion [12]. - The approval of a brain-machine interface for treating addiction marks a significant technological advancement in the industry [16]. Valuation Metrics - The overall valuation of the pharmaceutical sector is reported at 29.2 times earnings, ranking it 10th among 31 primary sectors [5][13]. - Specific companies within the sector have varying projected earnings per share (EPS) and price-to-earnings (PE) ratios, indicating diverse investment profiles [24].

Core Insights - The "Annual Outstanding Biopharmaceutical Enterprises" award recognizes companies with independent core technologies, continuous innovation, and effective transformation of research results into clinical or commercial applications [4] Group 1: Award Announcement - The "Annual Outstanding Biopharmaceutical Enterprises" award was announced during the "Technology Empowerment, Capital Breakthrough" sharing session held online by Gelonghui on December 22 [1] - Eight companies were awarded, including Baillie Tianheng (688506.SH), Dongyang Sunshine Pharmaceutical (06887.HK), Dongyao Pharmaceutical-B (01875.HK), and others, listed in alphabetical order [1] Group 2: Evaluation Criteria - The evaluation for the award was based on a comprehensive assessment of technical innovation, research and development strength, and achievement transformation [4] - The final results were derived through quantitative data analysis and expert review [4] Group 3: Purpose of the Award - Gelonghui aims to create a reference value ranking for listed companies and unicorns in the investment community with the "Golden Gelong Award" [4] - The award covers all listed companies and unicorns on major exchanges including the Hong Kong Stock Exchange, Shanghai Stock Exchange, Shenzhen Stock Exchange, New York Stock Exchange, and NASDAQ [4]